Product Program year 2024 Source: CMS Open Payments

Resmetirom

Drug Liver Disease

Open in the dashboard

General payments

$415,753

13,688 payments

Research payments

$1,278,635

144 payments

Through program year 2024, $415,753 in general payments and $1,278,635 in research payments were reported against Resmetirom (Liver Disease).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2024 General $415,753 13,688
2024 Research $1,278,635 144

Breakdown

Who paid General payments · program year 2024
  1. Madrigal Pharmaceuticals $415,753 13,688 payments
Top recipients General payments · program year 2024
  1. Naim Alkhouri Gastroenterology · Westlake, OH $6,348 2% · 16 payments
  2. Mazen Noureddin Gastroenterology · Houston, TX $4,274 1% · 6 payments
  3. Alina Allen Gastroenterology · Rochester, MN $4,267 1% · 5 payments
  4. Mary Rinella Gastroenterology · Chicago, IL $4,121 <1% · 4 payments
  5. Rohit Loomba Internal Medicine · La Jolla, CA $2,696 <1% · 5 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Gastroenterology Internal Medicine $186,697 46% · 3,288 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $49,661 12% · 1,005 practitioners
  3. Physician Assistant $38,761 9% · 746 practitioners
  4. Nurse Practitioner $21,843 5% · 459 practitioners
  5. Internal Medicine $17,888 4% · 309 practitioners

The top 5 of 75 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. California $61,704 15% · 768 recipients
  2. Texas $45,645 11% · 735 recipients
  3. Florida $36,862 9% · 739 recipients
  4. New York $35,161 8% · 535 recipients
  5. Pennsylvania $19,804 5% · 331 recipients

The top 5 of 52 states; each share is of general payments naming this product in 2024 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

7,350

Prescriptions dispensed, refills included

Drug cost

$31,398,511

Paid at the pharmacy, in all

Prescribers

356

With 11 or more claims of it

Medicare Part D drugs matched to RESMETIROM, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Rezdiffra Resmetirom Same name 356 7,350 $31,398,511

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Amanda Matthews Physician Assistant TX 118 $486,042 None on record
Naim Alkhouri Internal Medicine OH 98 $381,478 $6,348
Stephen Esposito Gastroenterology NY 95 $392,611 $207
Fred Fowler Gastroenterology NC 83 $332,937 $34
Daniel Brelian Gastroenterology CA 81 $316,449 $494

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
13,688 general · 144 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record